川北医学院学报2017，Vol.32Issue(6)：852-854,3.DOI:10.3969/j.issn.1005-3697.2017.06.012
重组人Ⅱ型肿瘤坏死因子受体抗体融合蛋白联合抗风湿药物治疗中重度银屑病的临床观察
The observation of rhTNFR:Fc combined with anti rheumatic drugs in the treatment of moderate to severe plaque psoriasis
摘要
Abstract
Objective:To observe the clinical effiency and safety of Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein(rhTNFR),combined with anti rheumatic drugs (methotrexate,leflunomide) in treatment of moderate to severe plaque psoriasis.Methods:78 patients of moderate to severe plaque psoriasis treated in our department were selected,45 cases of the observation group treated with rhTNFR:Fc combined with methotrexate (MTX) and leflunomide (LEF),33 cases of the control group treated with MTX + LEF.The severity index scores (PASI) and adverse reaction before treatment and at 2,4,8,12 and 24 weeks after treatment were observed.Results:After 8 weeks of treatment,the difference of PASI50 between the two groups was statistically significant(P ＜ 0.05).After 12 weeks and 24 weeks,the ratio of PASI50,PASI75 and PASI90 in the two groups was significantly higher than that in the control group,and the differences were statistically significant (P ＜ 0.05).There was no significant difference in the incidence of adverse reactions between the two groups (P ＞ 0.05).Conclusion:It's effective and safety of rhTNFR:Fc combined with MTX and LEF for the treatment of moderate to severe plaque psoriasis,which is worthy of clinical promotion.关键词
重组人Ⅱ型肿瘤坏死因子受体抗体融合蛋白/银屑病/甲氨喋呤/来氟米特Key words
rhTNFR/Fc/Psoriasis/Methotrexate/Leflunomide分类
医药卫生引用本文复制引用
张杰,李江涛,邓文郁,肖岚,陈芍..重组人Ⅱ型肿瘤坏死因子受体抗体融合蛋白联合抗风湿药物治疗中重度银屑病的临床观察[J].川北医学院学报,2017,32(6):852-854,3.基金项目
四川省卫计委科研项目(110599) （110599）
宜宾市科技局基金项目(2012SF004) （2012SF004）
